Related Experiment Videos
Guidelines for anti-emetic therapy: acute emesis.
A A Fauser1, M Fellhauer, M Hoffmann
1Clinic of BMT, Haematology and Oncology, Idar-Oberstein, Germany. office@bmt-center-io.de
European Journal of Cancer (Oxford, England : 1990)
|August 17, 1999
Summary
Effective anti-emetic therapy, primarily using serotonin receptor antagonists and corticosteroids, is crucial for cancer patients. These treatments improve quality of life by controlling chemotherapy-induced emesis, reducing hospitalizations and enhancing patient convenience.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anti-emetic therapy is essential for managing cancer patients.
- Controlling chemotherapy-induced emesis improves patient quality of life, reduces hospitalizations, and enhances convenience.
Purpose of the Study:
- To develop evidence-based consensus guidelines for preventing and treating chemotherapy-induced emesis.
- To provide recommendations for optimal anti-emetic use in oncology.
Main Methods:
- A panel of experts reviewed published literature.
- Consensus guidelines were developed based on evidence.
Main Results:
- Serotonin receptor antagonists and corticosteroids are the most effective, convenient, and well-tolerated anti-emetics.
- Combination therapy is recommended for highly emetogenic chemotherapy; single or combination agents for moderately to highly emetogenic regimens.
- Oral single doses are preferred when possible; dose escalation is not supported.
Conclusions:
- Appropriate anti-emetic use, guided by these recommendations, constitutes good medical practice.
- Adherence to guidelines offers a sensible economic approach to cancer care.
- Optimizing anti-emetic selection based on regimen emetogenicity is key.